Eloralintide
MetabolicAlso known as LY3841136
Evidence tier
Limited published literature
8 publications over 1 year · trials not yet curated
- Researched since
- 2025
- Publications
- 8
- Mean purity
- —
- Vendors listing
- 0
No indexed vendor publishes certificate records for Eloralintide that this index could read yet, so no purity comparison is possible.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2025 — 1 year of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
8 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
No vendor testing policy recorded yet — nothing recorded yet
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Eloralintide?
A selective, long-acting amylin receptor agonist peptide (LY3841136) in clinical development for obesity and weight management.
Studied in published research for obesity and weight management, as an amylin receptor agonist.
Regulatory status
Eloralintide is an investigational compound in clinical development and is not an approved medicine in the United States, United Kingdom or European Union. Products listed here are labeled by their vendors for laboratory research use only.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept — Molecular metabolism (2025)
Peer-reviewed article indexed in PubMed, published in Molecular metabolism (2025).
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial — Lancet (London, England) (2025)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2025).
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept — Diabetes, obesity & metabolism (2026)
Peer-reviewed article indexed in PubMed, published in Diabetes, obesity & metabolism (2026).
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials — Diabetes, obesity & metabolism (2026)
Peer-reviewed article indexed in PubMed, published in Diabetes, obesity & metabolism (2026).
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes — Peptides (2026)
Peer-reviewed article indexed in PubMed, published in Peptides (2026).
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs — Pharmacological research (2026)
Peer-reviewed article indexed in PubMed, published in Pharmacological research (2026).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|
Certificate records
No certificate records are indexed. Either none are published, or those published could not be read without an account.